ReviewHepatic oncology2018
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives.
Review in Hepatic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Phospholipid isotope tracing suggests β-catenin-driven suppression of phosphatidylcholine metabolism in hepatocellular carcinoma.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2024Article
- Phospholipid isotope tracing reveals β-catenin-driven suppression of phosphatidylcholine metabolism in hepatocellular carcinoma.bioRxiv : the preprint server for biology · 2023Article
- Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre.Journal of hepatocellular carcinoma · 2023Article
- Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma.BMC gastroenterology · 2022Article
- Complete response by patients with advanced hepatocellular carcinoma after combination immune/targeted therapy and transarterial chemoembolization: two case reports and literature review.Translational cancer research · 2022Article
- Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy.Journal of clinical and translational hepatology · 2022Review
- Anti-angiogenic effect of the combination of low-dose sorafenib and EGCG in HCC-induced Wistar rats.F1000Research · 2022Article
- Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation?Therapeutic advances in medical oncology · 2022Article
- Review
- LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression.Genes & genomics · 2020Article
- Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?Vaccines · 2020Review
- Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery.Hepatic oncology · 2020Article
- Review
- Comprehensive evaluation of SPATS2 expression and its prognostic potential in liver cancer.Medicine · 2020Article
- Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives.Advances in experimental medicine and biology · 2020Review
- SIRT4 silencing in tumor-associated macrophages promotes HCC development via PPARδ signalling-mediated alternative activation of macrophages.Journal of experimental & clinical cancer research : CR · 2019Article
- Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.BMC cancer · 2019Article
- Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies.Medicina (Kaunas, Lithuania) · 2019Review
- Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life.Cancers · 2019Review
- Cytoplasmic translocation of nuclear LSD1 (Hepatic oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, the REFLECT trial showed that lenvatinib is noninferior to sorafenib as front-line treatment. Following these trials, the therapeutic scenario will be dominated by anti-VEGFR drugs, with three different molecules showing a proven anticancer activity. Some open problems still remain and different immunotherapy trials are underway, following promising preliminary results. In this review we analyze: the most recent advancements about patients treated with sorafenib; the results of RESORCE and REFLECT trials; and the ongoing Phase III clinical trials. Finally, we discuss how they could address the current problems and possibly reshape the future of the systemic treatments for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.